These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12494247)

  • 21. Placebo response trajectories in short-term and long-term antipsychotic trials in schizophrenia.
    Potkin S; Agid O; Siu C; Watsky E; Vanderburg D; Remington G
    Schizophr Res; 2011 Nov; 132(2-3):108-13. PubMed ID: 21873032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies.
    Fusar-Poli P; Berger G
    J Clin Psychopharmacol; 2012 Apr; 32(2):179-85. PubMed ID: 22367656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials.
    Chen YF; Wang SJ; Khin NA; Hung HM; Laughren TP
    Pharm Stat; 2010; 9(3):217-29. PubMed ID: 20872622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iloperidone: a new option for the treatment of schizophrenia.
    Cutler AJ
    Expert Rev Neurother; 2009 Dec; 9(12):1727-41. PubMed ID: 19951132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials.
    Mallinckrodt CH; Tamura RN; Tanaka Y
    J Psychiatr Res; 2011 Sep; 45(9):1202-7. PubMed ID: 21453932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Signal detection and placebo response in schizophrenia: parallels with depression.
    Mallinckrodt CH; Zhang L; Prucka WR; Millen BA
    Psychopharmacol Bull; 2010; 43(1):53-72. PubMed ID: 20581800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placebo response in antipsychotic clinical trials: a meta-analysis.
    Rutherford BR; Pott E; Tandler JM; Wall MM; Roose SP; Lieberman JA
    JAMA Psychiatry; 2014 Dec; 71(12):1409-21. PubMed ID: 25321611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.
    Leucht S; Leucht C; Huhn M; Chaimani A; Mavridis D; Helfer B; Samara M; Rabaioli M; Bächer S; Cipriani A; Geddes JR; Salanti G; Davis JM
    Am J Psychiatry; 2017 Oct; 174(10):927-942. PubMed ID: 28541090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010.
    Agid O; Siu CO; Potkin SG; Kapur S; Watsky E; Vanderburg D; Zipursky RB; Remington G
    Am J Psychiatry; 2013 Nov; 170(11):1335-44. PubMed ID: 23896810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An assessment of the understanding and motivations of patients with schizophrenia about participating in a clinical trial.
    Chong SA; Ong YY; Subramaniam M; Abdin E; Marx CE; Campbell AV
    Contemp Clin Trials; 2009 Sep; 30(5):446-50. PubMed ID: 19393768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response.
    Leucht S; Chaimani A; Leucht C; Huhn M; Mavridis D; Helfer B; Samara M; Cipriani A; Geddes JR; Salanti G; Davis JM
    Schizophr Res; 2018 Nov; 201():315-323. PubMed ID: 29804928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe.
    Fleischhacker WW; Burns T;
    Psychopharmacology (Berl); 2002 Jun; 162(1):82-4. PubMed ID: 12107622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy of zotepine in schizophrenia: A meta-analysis of BPRS and improvement scale scores.
    Butler Andrew Wighton Claire P Welch Jack A Tweed Bill D Byrom Chris Reynolds A
    Int J Psychiatry Clin Pract; 2000; 4(1):19-27. PubMed ID: 24927305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The placebo arm in clinical studies for treatment of psychiatric disorders: a regulatory dilemma.
    Gispen-de Wied C; Stoyanova V; Yu Y; Isaac M; Pani L; de Andres-Trelles F
    Eur Neuropsychopharmacol; 2012 Nov; 22(11):804-11. PubMed ID: 22704716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified?
    Emsley R; Fleischhacker WW
    Schizophr Res; 2013 Nov; 150(2-3):427-33. PubMed ID: 24094881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The placebo effect: general information and specificities in psychiatry (depression and schizophrenia)].
    Corfmat J; Januel D; Braha S; Moulier V
    Encephale; 2012 Feb; 38(1):50-7. PubMed ID: 22381724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A random-effects mixture model for classifying treatment response in longitudinal clinical trials.
    Xu W; Hedeker D
    J Biopharm Stat; 2001 Nov; 11(4):253-73. PubMed ID: 12018779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis.
    Leucht S; Chaimani A; Mavridis D; Leucht C; Huhn M; Helfer B; Samara M; Cipriani A; Geddes JR; Davis JM
    Neuropsychopharmacology; 2019 Oct; 44(11):1955-1966. PubMed ID: 31212302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review: The biological basis of antipsychotic response in schizophrenia.
    Stone JM; Raffin M; Morrison P; McGuire PK
    J Psychopharmacol; 2010 Jul; 24(7):953-64. PubMed ID: 19939865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antipsychotic agents: what do meta analyses say?].
    Millet B
    Encephale; 2007 Jun; 33 Pt 3():S419-24. PubMed ID: 19101363
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.